RAPH — what changed in the latest 10-Q
A section-by-section comparison of RAPH's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +17 | −13 | ~35 | 29 |
| Controls & procedures | Text added/removed | 0 | 0 | ~3 | 4 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
We are a pharmaceutical research and development company focused on the discovery and clinical development of life-improving therapies based on purified cannabinoids. Our lead rheumatoid arthritis, or RA, formulation and our RaphaWell product are based on 98% purified cannabigerol, or CBG, formulate…
Our vision is to emerge as a pioneering company at the forefront of developing pharmaceutical and wellness formulations that harness the potential of purified CBG and related cannabinoid science. Our primary mission is to address unmet needs associated with inflammatory conditions, with a particular…
Our current RA development platform focuses on highly purified CBG as the principal cannabinoid component, formulated with sesame oil. Our research program has included pre-clinical work at Rambam and a U.S. proof-of-concept clinical study in patients with active RA. We intend to continue evaluating…
Our development strategy is centered on our proprietary purified CBG formulation and the scientific data generated through our research collaborations and clinical work.
We believe that our purified CBG-based platform may offer a differentiated approach for further research and product development. The results of our prior studies do not guarantee that we will receive regulatory approval for any pharmaceutical product candidate or that any future study will produce …
Text removed vs the prior filing · source: 10-Q · 2026-05-14
We are a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD, oil. Unless indicated otherwise, we plan on using oil derived from CBD strains with low levels of Tet…
Our vision is to emerge as a pioneering company at the forefront of formulating pharmaceutical drugs that harness the potential of purified cannabinoids and full-spectrum CBD oil. Our primary mission is to cater to the unmet medical requirements of patients grappling with various disorders, with a p…
Our discovery platform currently focuses the use of CBD oil, one of the cannabinoids in cannabis plants, as the active pharmaceutical ingredient, or API, for our RA product candidate and COVID-19 product candidate. Research results published in 2018 (“Translational Investigation of the Therapeutic P…
Over the last few years, pharmaceutical drug products that include parts of the cannabis plant have begun to receive regulatory approvals for use in patients suffering from certain disorders, as highlighted below.
●Nabiximols, better known under the tradename Sativex, is a botanical mouth spray consisting of natural THC and CBD extracts, that received approval in the United Kingdom in 2010 for the alleviation of multiple sclerosis, or MS, symptoms like spasticity, pain and overactive bladder.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice